Enzyme Immunoassay Market Report 2026

Enzyme Immunoassay Market Overview

• Enzyme Immunoassay market size has reached to $21.5 billion in 2025 • Expected to grow to $30.37 billion in 2030 at a compound annual growth rate (CAGR) of 7.1% • Growth Driver: Rising Burden Of Infectious Diseases Fueling The Growth Of The Market Due To Increasing Diagnostic Demand • Market Trend: Launch Of Fully Automated GFAP Assay Enhances Neurodegenerative Disease Profiling • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Enzyme Immunoassay Market?

Enzyme immunoassay is a highly sensitive laboratory method that involves the use of antibodies conjugated with enzymes to specifically detect and quantify target molecules such as proteins, hormones, or infectious agents within a given sample. This technique relies on the enzymatic reaction that produces a detectable signal, often a colorimetric change, which directly correlates to the amount of the substance being measured, allowing precise analysis for diagnostic or research purposes. The main types of products in enzyme immunoassay are reagents and kits, analyzers or instruments, and software and services. Reagents and kits are chemical substances or pre-packaged collections of chemicals used to detect, measure, or prepare other substances in laboratory and clinical testing. They support a wide range of specimen types, such as blood, saliva, urine, and others, and cater to diverse applications, including therapeutic drug monitoring, oncology, cardiology, endocrinology, infectious disease testing, autoimmune diseases, and others. Cater to diverse end users, including hospitals, blood banks, clinical laboratories, pharmaceutical and biotech companies, academic research centers, and others.

What Is The Enzyme Immunoassay Market Growth Forecast?

The enzyme immunoassay market size is expected to see strong growth in the next few years. It will grow to $30.37 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to development of fully automated eia analyzers, expansion of personalized medicine and precision diagnostics, increasing integration of laboratory information systems, rising adoption of software and data analysis tools, growing demand from academic and research institutions. Major trends in the forecast period include rising adoption of automated eia analyzers, growth in therapeutic drug monitoring applications, increasing use of multiplex testing and high-throughput assays, expansion of oncology and infectious disease testing, enhanced focus on laboratory data integration and workflow efficiency.

Global Enzyme Immunoassay Market Segmentation

1) By Product: Reagents And Kits, Analyzers Or Instruments, Software And Services 2) By Specimen: Blood, Saliva, Urine, Other Specimens 3) By Application: Therapeutic Drug Monitoring, Oncology, Cardiology, Endocrinology, Infectious Disease Testing, Autoimmune Diseases, Other Applications 4) By End-Use: Hospitals, Blood Banks, Clinical Laboratories, Pharmaceutical And Biotech Companies, Academic Research Centers, Other End-Uses Subsegments: 1) By Reagents And Kits: Antibodies, Antigens, Substrates, Buffers And Stabilizers 2) By Analyzers Or Instruments: Fully Automated EIA Analyzers, Semi-Automated EIA Systems, Microplate Readers, Washers And Incubators 3) By Software And Services: Data Analysis And Interpretation Software, Laboratory Information System Integration Tools, Instrument Calibration And Validation Services, Technical Support And User Training

What Is The Driver Of The Enzyme Immunoassay Market?

The growing burden of infectious diseases is expected to propel the growth of the enzyme immunoassay market going forward. Infectious diseases refer to illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites that can spread from person to person. The burden of infectious diseases is rising as antimicrobial resistance makes it increasingly difficult to treat common infections, leading to prolonged illness, higher medical costs, and increased mortality. Enzyme immunoassays are highly useful in the diagnosis of infectious diseases, as they enable the sensitive and specific detection of antigens or antibodies in patient samples, allowing for early identification, effective monitoring, and timely treatment of infections such as HIV, hepatitis, and influenza. For instance, in April 2025, according to the Minnesota Department of Health, a US-based government agency, the share of HIV cases among males aged 35 to 39 rose from 10% in 2023 to 17% in 2024, indicating a notable increase in this age group’s proportion of total cases. Therefore, the growing burden of infectious diseases is driving the growth of the enzyme immunoassay industry.

Key Players In The Global Enzyme Immunoassay Market

Major companies operating in the enzyme immunoassay market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Danaher Corporation, Merck KGaA, Siemens Healthineers AG, Becton Dickinson and Company (BD), PerkinElmer Inc., BioMérieux SA, Bio-Rad Laboratories Inc., Diasorin S.p.A., Bio-Techne Corporation, Quidel Corporation, Promega Corporation, Abcam plc, BioLegend Inc., Helena Laboratories Corporation, Cayman Chemical Company, Enzo Life Sciences Inc., RayBiotech Inc., MyBioSource Inc., Boster Biological Technology, Hycult Biotech, Calbiotech Inc.

Global Enzyme Immunoassay Market Trends and Insights

Major companies operating in the enzyme immunoassay market are focusing on introducing innovative enzyme immunoassay (EIA) solutions, such as fully automated enzyme immunoassays, to improve diagnostic accuracy, reduce manual errors, and enhance workflow efficiency in clinical laboratories. Fully automated enzyme immunoassays refer to diagnostic systems that perform the entire testing process automatically, enhancing speed, accuracy, and consistency in laboratory results. For instance, in July 2024, Fujirebio Holdings Inc., a Japan-based in vitro diagnostics (IVD) company, launched the fully automated Lumipulse G GFAP assay for research use only (RUO), expanding its neuro-biomarker portfolio. This RUO chemiluminescent enzyme immunoassay measures glial fibrillary acidic protein (GFAP) in human plasma and serum using the LUMIPULSE G platform and delivers results in just 35 minutes. It serves as an astrocytic biomarker implicated in conditions such as multiple sclerosis, Alzheimer’s and Parkinson’s diseases, stroke, and traumatic brain injury. This assay enhances Fujirebio’s expanding neuro menu, which already includes NfL, pTau217, and sTREM2, supporting comprehensive neurodegenerative disease profiling on a single automated system.

What Are Latest Mergers And Acquisitions In The Enzyme Immunoassay Market?

In January 2025, Medix Biochemica, a Finland-based developer of raw materials for in vitro diagnostics, acquired CANDOR Bioscience GmbH for an undisclosed amount. With this acquisition, Medix Biochemica aims to enhance its position as a leading global provider of raw materials for the in vitro diagnostics industry by expanding its immunoassay solutions portfolio with CANDOR Bioscience’s specialized expertise in high-performance blockers and assay optimization reagents, thereby enabling improved assay performance and greater support for diagnostic test development. CANDOR Bioscience GmbH is a Germany-based biotechnology company specializing in immunoassay solutions, particularly focusing on optimizing enzyme immunoassays and ELISA development.

Regional Outlook

North America was the largest region in the enzyme immunoassay market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Enzyme Immunoassay Market?

The enzyme immunoassay market consists of sales of enzyme-labeled antibodies, sample diluents, blocking reagents, microplate readers, ELISA test kits, robotic liquid handling systems, and plate washers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.